Search research articles
Contact Us
Filters
Showing results (41-50 of 66) with videos related to
Page
of 7
Sort By:
Rheumatology (Oxford, England)
|
August 12, 2024
A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment
Atul Deodhar, Alan J Kivitz, Marina Magrey, et al.
Advances in Therapy
|
April 16, 2022
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
Irene E van der Horst-Bruinsma, Kurt de Vlam, Jessica A Walsh, et al.
RMD Open
|
April 10, 2024
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
Victoria Navarro-Compán, Sofia Ramiro, Atul Deodhar, et al.
RMD Open
|
March 10, 2026
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
Philip J Mease, Joseph F Merola, Marina Magrey, et al.
RMD Open
|
June 2, 2022
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial
Victoria Navarro-Compán, James Cheng-Chung Wei, Filip Van den Bosch, et al.
Rheumatology and Therapy
|
December 19, 2025
Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials
John D Reveille, Martin Rudwaleit, Proton Rahman, et al.
RMD Open
|
October 19, 2021
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
Iain B McInnes, Koji Kato, Marina Magrey, et al.
The Journal of Rheumatology
|
June 15, 2026
Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results from Two Phase 3 Studies
Xenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
The New England Journal of Medicine
|
March 31, 2021
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
Iain B McInnes, Jaclyn K Anderson, Marina Magrey, et al.
JAMA Dermatology
|
October 1, 2020
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
Boni E Elewski, John W Baddley, Atul A Deodhar, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 66) with videos related to
Sort By:
Page
of 7
Rheumatology (Oxford, England)
|
August 12, 2024
A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment
Atul Deodhar, Alan J Kivitz, Marina Magrey, et al.
Advances in Therapy
|
April 16, 2022
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
Irene E van der Horst-Bruinsma, Kurt de Vlam, Jessica A Walsh, et al.
RMD Open
|
April 10, 2024
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
Victoria Navarro-Compán, Sofia Ramiro, Atul Deodhar, et al.
RMD Open
|
March 10, 2026
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
Philip J Mease, Joseph F Merola, Marina Magrey, et al.
RMD Open
|
June 2, 2022
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial
Victoria Navarro-Compán, James Cheng-Chung Wei, Filip Van den Bosch, et al.
Rheumatology and Therapy
|
December 19, 2025
Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials
John D Reveille, Martin Rudwaleit, Proton Rahman, et al.
RMD Open
|
October 19, 2021
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
Iain B McInnes, Koji Kato, Marina Magrey, et al.
The Journal of Rheumatology
|
June 15, 2026
Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results from Two Phase 3 Studies
Xenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
The New England Journal of Medicine
|
March 31, 2021
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
Iain B McInnes, Jaclyn K Anderson, Marina Magrey, et al.
JAMA Dermatology
|
October 1, 2020
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
Boni E Elewski, John W Baddley, Atul A Deodhar, et al.
Page
of 7